Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Date:1/22/2008

patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company will experience delays or difficulties in enrolling patients in the study and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in devel
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
(Date:8/19/2014)... RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ ... and Drug Administration (FDA) accepted for review the ... (FDC) of tiotropium and olodaterol delivered via the ... of long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. Tiotropium + olodaterol ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Cardiovascular Devices: Technologies ... , Offer a comprehensive view of the cardiovascular devices ... of the major types of cardiovascular diagnostic equipment, including ...
... , ... new market research report is available in its catalogue: ... Trends , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The ... a flurry of activity with pharmaceutical companies adding chiral ...
Cached Medicine Technology:Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 2Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 3Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 4Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 5Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 6Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 7Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 8Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 9Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 10Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 11Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 12Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5
(Date:8/20/2014)... Low market concentration, low price volatility, high ... the market for packaging design services. These factors foster ... indicating a moderate level of buyer power. “This level ... equal amount of leverage during negotiations,” according to IBISWorld ... exist for packaging design services . Buyers need ...
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 Kowa ... Expo West show to debut the new SL-17 portable ... a 20,000 lux white LED source controlled by an ... examination rooms. The SL-17 uses commercially available AAA rechargeable ... the previous SL-15 design requiring batteries designed specifically for ...
(Date:8/20/2014)... 20, 2014 This agreement will ... software defined networking, high availability cloud enablement, service, ... Resellers, while allowing OPEN-V to sell storageFOUNDRY’s expanding ... to work with OPEN-V on this distribution agreement ... manager distribution channels at storageFOUNDRY. "Nautilus is a ...
(Date:8/19/2014)... in Houston, Texas, is pleased to announce it is now ... with old fillings that need replacing, will benefit from the ... teeth. , From now on any cavities will be repaired ... amalgam free. Even though amalgam fillings have been deemed as ... children over the age of six, they do contain mercury ...
Breaking Medicine News(10 mins):Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... Sudden Cardiac Arrest,Association (SCAA) has appointed Chris Chiames as ... Chris join SCAA as we begin to implement our,strategic ... our goal of,eliminating preventable sudden cardiac arrest deaths (SCA) ... SCAA Board of Directors.,"Advancements in medical technology and treatment ...
... Sept. 7 With safety issues making,headlines, ... rugged,regulatory landscape. Organizations are relying on their ... affect production. Proper,staffing of quality roles is ... and a study by pharmaceutical benchmarking leader ...
... Employees Start! Lacing Up Their Walking Shoes -, ... fight against sedentary lifestyles by participating in the,American ... promote,walking and other healthy habits in the workplace. ... a Start! "walkforce" team to,participate in today,s Wilmington ...
... BELLEVILLE, ON, Sept. 7 /PRNewswire-FirstCall/ - Bioniche ... Canadian,biopharmaceutical company, today announced that it has ... Economic Development (RED) Program of the,Ontario Ministry ... grant,announced by the Honourable Leona Dombrowsky, Minister ...
... be compromised by new provisions enabling commercial companies to ... , A study, led by the Centre for International ... that, as a result of changes to how ... to provide patients with integrated and comprehensive services. , ...
... This week, American Red,Cross President and CEO, Mark W. ... of Operations Support., In this role, Sean will ... and Diversity, Finance and Information Technology to,ensure optimal integration ... of business., "The Red Cross will benefit from ...
Cached Medicine News:Health News:Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association 2Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:AstraZeneca Leads Local Walking Movement 2Health News:AstraZeneca Leads Local Walking Movement 3Health News:AstraZeneca Leads Local Walking Movement 4Health News:Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine 2Health News:Care reforms raise concerns over patient access to GP services 2Health News:Sean P. McLaughlin Joins Red Cross as Chief of Operations Support 2
... provides the most useful measurement for ... states. It is the preferred diagnostic ... patients who have experienced changes in ... dehydration. It is also used to ...
... HemoCue Hemoglobin Test Systems ... reliable quantitative hemoglobin results ... as a large hematology ... consists of either the ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: